Cisplatin (or carboplatin)
Sponsors
Pfizer, Biocad, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions
Cervical CancerCervical Cancer MetastaticCervical Cancer RecurrentHead & Neck CancerHead and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC)Neoadjuvant TherapyNon-Squamous Non-Small Cell Neoplasm of Lung
Phase 2
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
TerminatedNCT00977561
Start: 2010-04-30End: 2011-10-31Updated: 2013-02-25
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
NCT03912402
Start: 2018-12-25End: 2020-07-07Target: 49Updated: 2019-05-09
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
RecruitingNCT07601737
Start: 2026-04-20End: 2030-04-30Target: 182Updated: 2026-05-22
Phase 3
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
NCT03912389
Start: 2019-06-01End: 2023-12-31Target: 292Updated: 2020-09-17
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)
NCT03912415
Start: 2019-10-01End: 2024-12-01Target: 316Updated: 2020-09-18